Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0MTMQA
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
M-1231
|
|||||
| Synonyms |
M1231; M 1231
Click to Show/Hide
|
|||||
| Organization |
EMD Serono Research & Development Institute, Inc.; The University of Texas MD Anderson Cancer Center; Sutro Biopharma, Inc.
|
|||||
| Drug Status |
Phase 1
|
|||||
| Indication |
In total 3 Indication(s)
Esophageal cancer [ICD11:2B70]
Phase 1
Esophageal squamous cell carcinoma [ICD11:2B71]
Phase 1
Non-small cell lung cancer [ICD11:2C25]
Phase 1
|
|||||
| Drug-to-Antibody Ratio |
4
|
|||||
| Antibody Name |
Undisclosed
|
|||||
| Antigen Name |
Epidermal growth factor receptor (EGFR); Mucin-1 (MUC1)
|
Antigen Info | ||||
| Payload Name |
Undisclosed
|
|||||
| Linker Name |
Mc-Val-Cit-PABC
|
Linker Info | ||||
| Puchem SID | ||||||
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.